DexCom, Inc. (NASDAQ:DXCM) – Investment analysts at William Blair issued their Q1 2019 earnings per share estimates for shares of DexCom in a report issued on Wednesday. William Blair analyst M. Kaczor forecasts that the medical device company will post earnings per share of ($0.38) for the quarter. William Blair also issued estimates for DexCom’s Q2 2019 earnings at ($0.13) EPS.
DexCom (NASDAQ:DXCM) last posted its earnings results on Tuesday, February 27th. The medical device company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.07. DexCom had a negative net margin of 6.99% and a negative return on equity of 14.83%. The business had revenue of $221.00 million for the quarter, compared to analyst estimates of $217.82 million.
DexCom (DXCM) traded up $0.42 during trading hours on Thursday, reaching $56.14. 1,835,100 shares of the company were exchanged, compared to its average volume of 1,269,055. DexCom has a 1-year low of $42.62 and a 1-year high of $86.32. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84. The firm has a market cap of $4,842.24, a price-to-earnings ratio of -95.15 and a beta of 0.21.
In related news, EVP Richard Doubleday sold 1,638 shares of DexCom stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $56.32, for a total transaction of $92,252.16. Following the completion of the transaction, the executive vice president now directly owns 65,049 shares of the company’s stock, valued at approximately $3,663,559.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Terrance H. Gregg sold 10,000 shares of DexCom stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $56.86, for a total transaction of $568,600.00. Following the transaction, the insider now directly owns 484,559 shares of the company’s stock, valued at $27,552,024.74. The disclosure for this sale can be found here. Insiders have sold a total of 34,153 shares of company stock valued at $1,953,327 over the last ninety days. 1.70% of the stock is owned by insiders.
Hedge funds have recently made changes to their positions in the stock. American International Group Inc. bought a new position in DexCom during the 4th quarter valued at about $116,000. Thompson Davis & CO. Inc. bought a new position in DexCom during the 4th quarter valued at about $137,000. The Manufacturers Life Insurance Company increased its position in DexCom by 12.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock valued at $238,000 after acquiring an additional 354 shares in the last quarter. Zions Bancorporation increased its position in DexCom by 36,222.2% in the 3rd quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock valued at $160,000 after acquiring an additional 3,260 shares in the last quarter. Finally, Marco Investment Management LLC acquired a new stake in DexCom in the 4th quarter valued at about $201,000.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.